I am committed to a career focused on basic and translational research to improve the treatment of lung cancer. My work uses a variety of experimental and analytical approaches to define and characterize genetic subsets of lung cancer with the goal of identifying novel precision treatment approaches. Specifically, my previous work has characterized gene expression profiles, signaling pathways, and drug sensitivity patterns that define lung adenocarcinomas that have lost the LKB1 tumor suppressor. This gene, a serine-threonine kinase also known as STK11, is lost in approximately 30% of lung adenocarcinomas and has recently been shown to confer significant clinical resistance to immunotherapy. My current work applies high throughput functional genomics approaches to model systems of LKB1 loss with the goal of 1) identifying novel clinical targets for LKB1 deficient lung cancer, and 2) discover mechanisms of resistance to immune checkpoint inhibition in this subset of tumors.